Maze Therapeutics (NASDAQ:MAZE) Earns “Buy” Rating from BTIG Research

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reissued by research analysts at BTIG Research in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $46.00 price target on the stock. BTIG Research’s price objective would indicate a potential upside of 45.06% from the company’s current price.

A number of other analysts have also commented on the company. Guggenheim boosted their price objective on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Mizuho raised Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. Finally, Truist Financial began coverage on Maze Therapeutics in a research note on Tuesday, March 17th. They set a “buy” rating and a $68.00 price objective on the stock. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $64.11.

Maze Therapeutics Price Performance

Shares of NASDAQ MAZE opened at $31.71 on Wednesday. The company has a 50-day moving average price of $45.81 and a 200-day moving average price of $37.51. The stock has a market capitalization of $1.53 billion, a P/E ratio of -9.82 and a beta of 4.47. Maze Therapeutics has a 1 year low of $6.71 and a 1 year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08.

Insiders Place Their Bets

In other news, SVP Amy Bachrodt sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.58, for a total value of $405,800.00. Following the completion of the transaction, the senior vice president directly owned 12,965 shares of the company’s stock, valued at $526,119.70. This represents a 43.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Atul Dandekar sold 72,400 shares of the stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total value of $2,936,544.00. Following the sale, the insider directly owned 10,503 shares of the company’s stock, valued at $426,001.68. The trade was a 87.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 245,000 shares of company stock valued at $10,504,792 in the last 90 days.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of MAZE. Royal Bank of Canada increased its position in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics during the 4th quarter worth $39,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Maze Therapeutics in the 4th quarter worth about $43,000. California State Teachers Retirement System grew its position in Maze Therapeutics by 138.0% during the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after buying an additional 766 shares during the period. Finally, Ameritas Investment Partners Inc. grew its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the period.

Maze Therapeutics News Roundup

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Maze announced positive topline Phase 2 HORIZON results for MZE829 showing clinically meaningful uACR reductions (35.6% mean reduction in broad AMKD at week 12; stronger reductions in FSGS and non‑diabetic subgroups) and said it will advance MZE829 into a pivotal program — a clear de‑risking milestone for a lead asset. Maze Announces Positive Topline Data
• Positive Sentiment: Analysts reacted with bullish calls and higher targets — HC Wainwright raised its price target to $110 and BTIG reaffirmed a buy with a $46 target — supporting upside expectations if pivotal plans succeed. Analyst Upgrades
• Positive Sentiment: Quarterly results: Maze beat consensus EPS (reported ($0.65) vs. ($0.73) est.) and reiterated a strong cash position (~$360M), which management says funds operations into 2028 — reduces near‑term financing risk. Q4 and FY2025 Report
• Neutral Sentiment: Corporate governance update: Neil Kumar (BridgeBio founder/CEO) joined Maze’s board — signal of industry expertise but longer‑term impact on strategy is uncertain. Board Addition
• Negative Sentiment: Several outlets described the Phase 2 readout as “mixed” and reported a near‑one‑third drop in market cap as investors parsed subgroup vs overall results and durability/clinical design questions — headline framing triggered aggressive profit‑taking. Mixed Midstage Data Coverage
• Negative Sentiment: An executive disclosed a ~$736K insider sale (15,000 shares via option exercise) reported March 20 — such filings can amplify selling pressure during volatile moves even if routine. Insider Sale Report
• Negative Sentiment: Johnson Fistel announced an investigation into potential claims against Maze executives related to investor losses — legal scrutiny can prolong volatility and increase perceived risk. Shareholder Investigation Notice

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.